

Collaborate.

Network.

**Optimize.** 

# 2019 Schedule



collaborate on tactics and strategies to drive efficiencies and outcomes.

## Designed to address current market challenges and opportunities, the AMCP Partnership Forums:

- Take a proactive, collaborative approach to solving important issues and challenges
- Represent opportunities for payers, manufacturers, and other stakeholders to work together on common goals and interests, and create actionable results
- Gain consensus on tactics to address key challenges or opportunities, as well as how to remove barriers to improve patient care and optimize value for all stakeholders
- · Have high visibility among industry stakeholders and policy-makers

TOPICS AND DATES



### Partnering with AMCP, you'll engage with more than 8,000 managed care pharmacists, physicians, nurses, student pharmacists and other professionals. Here is a partial list of partners from 2018:

AbbVie • Aetna • Allergan • Amgen • Blue Cross Blue Shield Association • Boehringer Ingelheim • Bristol-Myers Squibb • CareFirst Blue Cross Blue Shield • Celgene Corporation • CVS Health • Express Scripts • Foundation Medicine • Genentech Healthcare • Gilead • GlaxoSmithKline • Group Health • Humana • Kaiser Permanente • Lilly • MedImpact • Merck & Co. • National Pharmaceutical Council (NPC) • Novartis • Novo Nordisk • OmedaRx • Pharmaceutical Research Manufacturers of America (PhRMA) • Precision for Value • Premera • Sanofi • Takeda • Takeda Oncology • UPMC Health Plan • Xcenda and more...

#### Pharmacy and Therapeutics (P&T) Practices: What's Next?

It has been nearly 20 years since AMCP and other stakeholders adopted the *Principles for a Sound Formulary System*. Since that time, requirements for pharmacy and therapeutics committees (P&T) have been adopted by the Medicare Part D program, health insurance marketplace plans, commercial health plans, Medicaid programs, and other public payers. Changes and evolution in the health care system, including a focus on value-based care, suggest the need for updated recommendations from a broad stakeholder coalition. This Forum will provide a venue to consider P&T practices that reflect the current health care system and provide recommendations to allow for a transparent P&T process in today's health care system.

March 28, 2019 | Marriott Marquis San Diego Marina (held with AMCP's Annual Meeting)

#### **Optimizing Prior Authorization for Appropriate Medication Selection**

We will examine how to improve decision making for prior authorization and step therapy based on current market dynamics and considerations to ensure patients receive the most appropriate medications. The forum will develop multi-stakeholder recommendations including: the impact of PA on patient outcomes, the return on investment for technology adoption, and ways to ensure good outcomes through policy and activities by the health care system.

June 25–26, 2019 | Hilton Mark Center | Alexandria, VA

### Digital Therapeutics: What Are They and Where Do They Fit in Pharmacy and Medical Benefits?

Digital therapeutics with web and designed based applications are emerging as a means to treat conditions by engaging people to improve health and wellness. In some cases, these therapeutics are preventive to stop a disease or improve outcomes in certain chronic conditions including cancer, diabetes, and heart disease. Other areas for digital therapeutics have emerged for birth control and to manage opioid addiction. They typically focus on ways to modify a person's environment or behavior to increase patient engagement, improve adherence to medications and possibly reduce hospitalizations or prevent other expensive health interventions. But where do these fit in terms of a pharmacy or a medical benefit for insurance coverage? This partnership forum will consider these important emerging issues to provide recommendations to inform this growing area. *September 17–18, 2019 Hilton Mark Center Alexandria, VA* 

#### What's Next for Specialty Medication Benefit Design and Reimbursement

Current inefficiencies in the health care system create administrative burdens for patients, providers, and payers, and often result in additional unnecessary costs. As a result, the government and private sectors are examining new reimbursement and benefit designs to pay for medications, including re-examining the Medicare Part B and Medicaid programs. Before implementing major changes, however, stakeholders must carefully analyze the potential impact these reforms will have on patient care, access to medications, and the overall health care system. This forum will make recommendations and considerations for ways that benefit design and reimbursement may evolve without compromising patient access and care. *December 10–11, 2019* | *Hilton Mark Center* | *Alexandria, VA* 



4

#### For additional information, contact: